European Stroke Organizational Report
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
During the past 3 years, the European Stroke Organisation (ESO) has seen the launch of its annual congress, its growing attendance, and a boom in the society’s membership with currently >7000 professionals enrolled as members. Within this 3-year period, 36 National Stroke societies throughout the world have joined as associate members with the expressed intent to adhere to and promote stroke diagnosis and treatment according to ESO stroke treatment standards.
At the 2017 ESO Conference (ESOC) held in Prague, and chaired by Martin Dichgans, the number of submitted abstracts was >1800, and the number of participants exceeded 4000 clinicians, researchers, and other healthcare professionals. Many investigators chose ESOC 2017 to present landmark results of their studies, including >12 randomized controlled trials. Tudor Jovin and Raul G. Nogueira presented the final results from the DAWN trial (Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo) reporting superior functional outcomes at 90 days with endovascular thrombectomy plus medical management compared with medical management alone in carefully selected patients with ischemic stroke and a proximal intracranial artery occlusion, treated 6 to 24 hours after last seen. Two trials on patent foramen ovale closure were presented: CLOSE (Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence) and Gore-REDUCE (GORE® HELEX® Septal Occluder / GORE® Septal …